Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
05 mai 2023 16h06 HE
|
Mereo BioPharma Group plc
LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
13 avr. 2023 08h00 HE
|
Mereo BioPharma Group plc
LONDON, April 13, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
28 mars 2023 16h30 HE
|
Mereo BioPharma Group plc
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
21 mars 2023 06h30 HE
|
Mereo BioPharma Group plc
Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional...
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
08 févr. 2023 07h00 HE
|
Mereo BioPharma Group plc
LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
08 nov. 2022 07h00 HE
|
Mereo BioPharma Group plc
LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
02 nov. 2022 16h01 HE
|
Mereo BioPharma Group plc
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
28 oct. 2022 07h00 HE
|
Mereo BioPharma Group plc
Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024...
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
24 oct. 2022 16h30 HE
|
Mereo BioPharma Group plc
LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology,...
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
21 oct. 2022 07h00 HE
|
Mereo BioPharma Group plc
Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value Details Rubric’s...